Hyperoxaluria Type
📧 Sign up to get email alerts when something new happens for Hyperoxaluria Type.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
A prospective observational study of patients with Primary Hyperoxaluria Type 1 (PH1), sponsored by Alnylam, that is currently not recruitin…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function [Phase 2]
Phase 2 trial update showing results for Nedosiran in pediatric patients from birth to 11 years with Primary Hyperoxaluria (Types 1–3); the …
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine) [Phase 1, Phase 2]
Arbor Biotechnologies is conducting a Phase 1/2 trial of ABO-101 for Primary Hyperoxaluria Type 1, and the study is currently recruiting und…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD [Phase 2]
This is a Phase 2 clinical trial update describing the safety and efficacy assessment of DCR-PHXC for Primary Hyperoxaluria Type 1 in patien…
-
CLINICAL_TRIALS trial_result · 2025-07-22Clinical Trial Update: Treatment of Primary Hyperoxaluria Type 1 With Nedosiran
This clinical trial update notes that a study of nedosiran for Primary Hyperoxaluria Type 1 is no longer available.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Long Term Extension Study in Patients With Primary Hyperoxaluria [Phase 3]
A Phase 3 long-term extension study in patients with Primary Hyperoxaluria is ongoing but not recruiting, sponsored by Dicerna Pharmaceutica…
-
CLINICAL_TRIALS research · 2025-05-16Clinical Trial Update: Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1) [EARLY_Phase 1]
This is an early-phase 1 clinical trial evaluating YOLT-203 for primary hyperoxaluria type 1, currently recruiting at RenJi Hospital.
-
FDA approval · 2025-04-04FDA Approved: OXLUMO — Supplemental Application (Alnylam Pharmaceuticals, Inc.)
The FDA approved a supplemental application for OXLUMO (lumasiran) from Alnylam Pharmaceuticals, authorizing an updated approved product.
-
CLINICAL_TRIALS research · 2025-03-03Clinical Trial Update: Oxalate Excretion Profile in Patients with a Heterozygous Mutation of the AGXT (alanine-glyoxylate Aminotransferase) Gene [NA]
A recruiting clinical trial studying oxalate excretion in patients with a heterozygous AGXT gene mutation, related to primary hyperoxaluria …
-
CLINICAL_TRIALS trial_result · 2024-12-02Clinical Trial Update: Natural History of Patients With PH3 and a History of Stone Events
This completed clinical trial update describes the natural history of patients with Primary Hyperoxaluria Type 3 and a history of stone even…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients [Phase 1]
A Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of DCR-PHXC in Primary Hyperoxaluria Type 3 has compl…
-
CLINICAL_TRIALS withdrawal · 2024-07-11Clinical Trial Update: A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1) [Phase 1]
A clinical trial update indicates that the Phase 1 study of DCR-PH1 for Primary Hyperoxaluria Type 1 has been terminated.
-
CLINICAL_TRIALS research · 2024-06-18Clinical Trial Update: Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3 [Phase 3]
Phase 3 clinical trial update evaluating the efficacy and safety of stiripentol in patients aged 6 years and older with Primary Hyperoxaluri…
-
CLINICAL_TRIALS trial_result · 2024-05-22Clinical Trial Update: A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 [Phase 2]
A Phase 2 trial evaluating DCR-PHXC in children and adults with Primary Hyperoxaluria Type 1 and Type 2 has completed, with results posted o…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1 [Phase 2]
Phase 2 extension study results for Lumasiran (ALN-GO1) in participants with Primary Hyperoxaluria Type 1 have been reported. The trial is c…
-
FDA approval · 2023-09-19FDA Approved: OXLUMO — Supplemental Application (Alnylam Pharmaceuticals, Inc.)
The FDA approved a supplemental application for OXLUMO (LUMASIRAN) submitted by Alnylam Pharmaceuticals.
-
FDA approval · 2022-10-06FDA Approved: OXLUMO — Supplemental Application (Alnylam Pharmaceuticals, Inc.)
The FDA approved a supplemental application for OXLUMO (lumasiran) submitted by Alnylam Pharmaceuticals, resulting in changes to the product…
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 [Phase 3]
A Phase 3 study evaluating Lumasiran for advanced Primary Hyperoxaluria Type 1 has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2021-07-19Clinical Trial Update: A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 [Phase 3]
A Phase 3 trial of lumasiran in infants and young children with primary hyperoxaluria type 1 has completed and posted results in 2021.
-
CLINICAL_TRIALS trial_result · 2021-01-19Clinical Trial Update: A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 [Phase 3]
Phase 3 trial results for lumasiran in children and adults with Primary Hyperoxaluria Type 1 have been completed, with results posted in Jan…
-
FDA approval · 2020-11-23FDA Approved: OXLUMO — Original Application (Alnylam Pharmaceuticals, Inc.)
FDA approved OXLUMO (lumasiran) from Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1.
-
EMA approval · 2020-10-16First treatment for rare condition primary hyperoxaluria type 1
EMA announces the first treatment for the rare genetic disorder primary hyperoxaluria type 1.
-
CLINICAL_TRIALS trial_result · 2020-01-30Clinical Trial Update: Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1 [Phase 1, Phase 2]
Phase 1/2 trial of Lumasiran in healthy adults and patients with Primary Hyperoxaluria Type 1 has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2016-07-13Clinical Trial Update: IDENTIFICATION OF A MULTI-ANALYTE PROFILE FOR PRIMARY HYPEROXALURIA AND COMPARISON WITH HEALTHY SIBLINGS AND IDIOPATHIC HYPERCALCIURIA [NA]
A completed clinical trial identifying a multi-analyte biomarker profile for Primary hyperoxaluria type 1 and comparing it with healthy sibl…
-
CLINICAL_TRIALS trial_result · 2013-01-01Clinical Trial Update: Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria [Phase 2]
Phase 2 trial evaluating betaine to reduce urine oxalate in patients with Type 1 primary hyperoxaluria. Results were posted in 2013.